Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a "Safe Corridor" after kidney transplantation?
Guy El HelouBrian LahrRaymund R RazonablePublished in: Transplant infectious disease : an official journal of the Transplantation Society (2020)
The contrasting outcomes of lymphocyte manipulation after solid organ transplantation are allograft rejection and infections, commonly with cytomegalovirus (CMV). Peripheral blood absolute lymphocyte count (ALC) may serve as a predictive marker for these outcomes. Using a retrospective review of clinical and laboratory dataset, we aimed to determine whether a range of ALC (termed "safe ALC corridor") exists where CMV infection and rejection outcomes are minimal in a cohort of 381 kidney transplant recipients. In an extended Cox model using a time-dependent covariate for peripheral blood ALC, a value below the cut-off of 610 cells/uL was associated with the development of CMV infection both in the overall cohort (Hazard Ratio [HR] 2.25 (95% confidence internal [CI] 1.02-4.96; P = .043) and the subgroup of high-risk CMV D+/R- mismatch patients (HR 2.91 [95% CI 1.09-7.77]; P = .033). In contrast, a time-dependent Cox analysis did not show any significant association between ALC and rejection (per IQR decrease, HR 1.2 [95% CI: 0.76-1.9]; P = .434). Accordingly, a "safe ALC corridor" could not be defined. In conclusion, a low peripheral blood ALC (ie, threshold of 610 cells/uL) can be used to stratify the risk of CMV disease after kidney transplantation.
Keyphrases
- peripheral blood
- induced apoptosis
- cell cycle arrest
- epstein barr virus
- end stage renal disease
- ejection fraction
- newly diagnosed
- magnetic resonance
- endoplasmic reticulum stress
- type diabetes
- prognostic factors
- clinical trial
- oxidative stress
- magnetic resonance imaging
- randomized controlled trial
- kidney transplantation
- signaling pathway
- herpes simplex virus
- cell therapy
- adipose tissue
- weight loss
- patient reported outcomes
- skeletal muscle
- insulin resistance
- bone marrow
- study protocol
- open label